MBRX MOLECULIN BIOTECH INC Product Launches 8-K Filing 2024 - Phase 2 Study Commencement Moleculin Biotech, Inc. announced the commencement of a Phase 2 study for the treatment of glioblastoma.Get access to all SEC 8-K filings of the MOLECULIN BIOTECH INC